Status:

RECRUITING

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Lead Sponsor:

Enlivex Therapeutics Ltd.

Conditions:

Arthritis, Psoriatic

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

Detailed Description

Psoriatic Arthritis (PsA) is a prevalent chronic inflammatory disease that mainly affects the synovial joints, and leads to inflammatory arthritis, in addition to skin manifestations. If left untreate...

Eligibility Criteria

Inclusion

  • Diagnosed with PsA.
  • Stage 1 patients:
  • At least one joint resistant to standard PsA treatments and on a stable dose of approved PsA treatment for at least 3 months prior to treatment.
  • Stage 2 patients:
  • At least one symptomatic joint following attempt of intra-articular injection of corticosteroids, with insufficient response.
  • Acceptable blood tests- Complete Blood Count (CBC), electrolytes, adequate renal function, adequate liver function.

Exclusion

  • Prior intra-articular injection to the target joint of steroids, hyaluronate or other drugs within 3 months prior to treatment.
  • Any significant injury to the target joint within the 6 months prior to treatment, or any surgery to the target joint within the 12 months prior to treatment.
  • Findings of acute fractures, severe loss of bone density, chondrocalcinosis and/or severe bone or joint deformity in the target joint.
  • Evidence of active local infection in the target joint.
  • Concomitant rheumatic, inflammatory or autoimmune disease other than PsA.
  • Other limb pain of unknown etiology.
  • Any evidence of clinically significant active infection.
  • Major medical condition as detailed in the protocol.

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2026

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT06522035

Start Date

August 1 2024

End Date

September 1 2026

Last Update

August 19 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Rambam Medical Center

Haifa, Israel, 3109601

2

Carmel Medical Center

Haifa, Israel, 3436212

3

Meir Medical Center

Kfar Saba, Israel, 4428164

4

Tel Aviv Sourasky Medical Center - Ichilov

Tel Aviv, Israel, 6423906